MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

Stability Notes

Dutasteride is absorbed through the skin, therefore, women, children and adolescents must avoid contact with leaking capsules.

Provenance

This compatibility recommendation is derived from Avodart 500microgram capsules (GlaxoSmithKline UK Ltd).

Stability Notes

Dutasteride is absorbed through the skin, therefore, women, children and adolescents must avoid contact with leaking capsules.

Provenance

This compatibility recommendation is derived from Avodart 500microgram capsules (GlaxoSmithKline UK Ltd).

Stability Notes

Dutasteride is absorbed through the skin, therefore, women, children and adolescents must avoid contact with leaking capsules.

Provenance

This compatibility recommendation is derived from Avodart 500microgram capsules (GlaxoSmithKline UK Ltd).

Stability Notes

No special requirements for storage.

Provenance

This compatibility recommendation is derived from all strengths of Lyrica capsules (Viatris UK Healthcare Ltd).

Stability Notes

No special requirements for storage.

Provenance

This compatibility recommendation is derived from all strengths of Lyrica capsules (Viatris UK Healthcare Ltd).

Stability Notes

No special requirements for storage.

Provenance

This compatibility recommendation is derived from all strengths of Lyrica capsules (Viatris UK Healthcare Ltd).

Stability Notes

No special requirements for storage.

Provenance

This compatibility recommendation is derived from all strengths of Lyrica capsules (Viatris UK Healthcare Ltd).

Stability Notes

No special requirements for storage.

Provenance

This compatibility recommendation is derived from all strengths of Lyrica capsules (Viatris UK Healthcare Ltd).

Stability Notes

There are no stability notes available for this medicine.
Print this list

Medicines under this category are suitable for use inside MCAs, although this is likely to be an off-label use.
Medicines under this category can theoretically be used inside an MCA; however, mitigations may need to be considered.
Medicines under this category are not suitable for use inside MCAs.
We do not have stability information for these medicines and therefore cannot make a recommendation on suitability in an MCA.